Commodore Capital LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 37 US equity positions worth $2.0bn in its Q3 2025 13F filing. The largest position was MERUS N V at 16.2% of the reported book, followed by NUVALENT INC and XENE. Against the Q2 2025 filing, it opened 7 new positions, added to 9 and reduced 9 among the top 37 holdings.
What did Commodore Capital LP own in Q3 2025? Top 37 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 16.2% | $331.9m | 3,525,000 | 0% | held | |
| 2 | NUVALENT INC | 5.9% | $121.1m | 1,400,000 | 2% | added | |
| 3 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.3% | $108.4m | 2,700,000 | -11% | reduced |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.1% | $104.1m | 7,250,000 | 214% | added |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 4.7% | $96.1m | 4,692,809 | 0% | held |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.6% | $93.9m | 2,338,287 | 1% | added |
| 7 | ALKS ALKERMES PLC | Healthcare | 4.5% | $92.9m | 3,096,754 | 26% | added |
| 8 | SLNOEUR SOLENO THERAPEUTICS INC | 4.5% | $91.3m | 1,350,000 | 121% | added | |
| 9 | RLAY RELAY THERAPEUTICS INC | Healthcare | 4.3% | $88.7m | 17,000,000 | 27% | added |
| 10 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 3.8% | $78.3m | 3,028,335 | -12% | reduced |
| 11 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.4% | $69.1m | 2,850,000 | -14% | reduced | |
| 12 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 3.4% | $69.1m | 3,200,000 | -34% | reduced |
| 13 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 3.3% | $68.1m | 1,025,000 | -5% | reduced |
| 14 | PHVS PHARVARIS N V | 2.9% | $60.3m | 2,418,476 | 27% | added | |
| 15 | CDTX CIDARA THERAPEUTICS INC | 2.7% | $56.0m | 585,000 | -50% | reduced | |
| 16 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 2.7% | $55.4m | 4,075,478 | – | new |
| 17 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.3% | $47.2m | 3,375,000 | 9% | added |
| 18 | 430 TERNS PHARMACEUTICALS INC | 2.1% | $42.8m | 5,700,000 | – | new | |
| 19 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.1% | $42.5m | 750,000 | 0% | held |
| 20 | BRD1EUR MIND MEDICINE MINDMED INC | 1.9% | $38.0m | 3,225,000 | -36% | reduced | |
| 21 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.7% | $34.9m | 3,780,055 | -4% | reduced |
| 22 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.6% | $33.7m | 1,753,054 | 23% | added |
| 23 | SYRE SPYRE THERAPEUTICS INC | 1.6% | $33.3m | 1,988,084 | 0% | held | |
| 24 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.5% | $30.3m | 500,000 | 0% | held |
| 25 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 1.2% | $25.6m | 1,000,000 | – | new |
| 26 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.2% | $24.5m | 7,692,300 | 0% | held |
| 27 | LB PHARMACEUTICALS INC | 1.2% | $23.7m | 1,500,000 | – | new | |
| 28 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.6% | $12.6m | 1,500,000 | 0% | held |
| 29 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.6% | $11.5m | 290,000 | 0% | held |
| 30 | PEPG PEPGEN INC | Healthcare | 0.5% | $10.9m | 2,357,319 | – | new |
| 31 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 0.5% | $9.6m | 800,000 | – | new |
| 32 | SABS SAB BIOTHERAPEUTICS INC | 0.4% | $8.8m | 4,401,500 | – | new | |
| 33 | IKT INHIBIKASE THERAPEUTICS INC | 0.4% | $8.7m | 5,397,488 | 0% | held | |
| 34 | PERCEPTIVE CAP SOLUTIONS COR | 0.4% | $7.9m | 750,000 | 0% | held | |
| 35 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.3% | $6.1m | 483,000 | 0% | held |
| 36 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $5.6m | 1,575,000 | 0% | held | |
| 37 | CBIO CRESCENT BIOPHARMA INC. | 0.3% | $5.4m | 450,829 | -1% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.